“Blue-Sky” Proposal For Molecular Dx Reimbursement Piques Interest
This article was originally published in The Gray Sheet
Executive Summary
A top health insurance executive recently floated an out-of-the-box proposal to give molecular diagnostic makers a fighting chance to collect the clinical utility data that is increasingly needed to establish long-term reimbursement.